Workspace Health and Safety

 

 

Biogen takes the wellbeing of our employees very seriously, and we believe each and every employee plays a role in creating a safe and healthy workplace. Our employees have varied roles and functions, which is why we empower each of them to promote a safe working environment, regardless of whether work happens in the lab, in an office or in a manufacturing plant. Our policies and practices are crafted to protect not only our employees, but also the surrounding communities in which we operate.

In 2019 Biogen continued to make significant progress integrating Human Performance (Hu) into our Environment, Health and Safety (EHS) programs. Hu is founded on the principle that, when it comes to safety, workers are part of the solution. Hu encourages employees to collaboratively engage in proactive problem solving through practices such as Open Reporting and Work Observation and Risk Conversations (WORCs). By engaging and empowering our employees through such programs, we believe that we can help change how the entire industry approaches safety performance and risk management.


For the past several years, we’ve made significant progress in our efforts to track Biogen’s health and safety performance. In 2018 we implemented new, leading indicators towards measuring safety as a capacity, not a result. For example, we’re now evaluating proactive versus reactive activity trends. We’re also changing the way we monitor high-risk training completion and tracking the age/completion of actions tied to higher risk events. Our Days Away Case Rate (DACR) continues to track the frequency of work-related illnesses and injuries that lead to an absence from work. We’re proud to say that in 2019, our DACR and our Total Recordable Injury Rate (TRIR) were both below the industry average. For 2019 Biogen’s DACR was 0.11 (U.S. industry average at 0.4 in 2018) and TRIR was 0.28 (U.S. industry average at 1.6 in 2018). Biogen exceeded expectations in its 2019 DACR target of being in the top quartile in a peer group of 15 pharmaceutical/biotechnology leaders, achieving second place in the group.

 

 

 

 

Building on progress in the implementation of Hu and our DACR, which is below average and exceeds expectations, Biogen will begin a focused effort to reduce employees’ risk of a serious incident or fatality (SIF). A SIF is defined as any incident that results in or has the potential to result in a fatality, life-altering or life-threatening injury. We [know/understand] that potential SIFs are not discrete events. The conditions, practices and other factors that lead to or contribute to the causation of a SIF are present before the event. In 2020 Biogen will begin these efforts by first identifying those activities that present the highest risk of a SIF to employees. The next phase will involve evaluating these activities and identifying high value controls to reduce or eliminate the risk. Our target in 2020 will be to reduce the number of Critical Tasks by 30 percent using High Value Controls.


Learn more about our Manufacturing.